Time filter

Source Type

Sun Y.,Hebei University of Science and Technology | Zhan L.,Hebei University of Science and Technology | Cheng X.,North China Pharmaceutical Group New Drug Research and Development Co. | Zhang L.,Hebei Medical University | And 3 more authors.
Cellular and Molecular Neurobiology | Year: 2016

The NMDA receptor is the most widely studied ionotropic glutamate receptor, and it is central to many physiological and pathophysiological processes in the central nervous system. GluN2A is one of the two main types of GluN2 NMDA receptor subunits in the forebrain. The proper activity of GluN2A is important to brain function, as the abnormal regulation of GluN2A may induce some neuropsychiatric disorders. This review will examine the regulation of GluN2A by endogenous and exogenous regulators in the central nervous system. © 2016 Springer Science+Business Media New York


PubMed | Hebei University of Science and Technology, Hebei Medical University and North China Pharmaceutical Group New Drug Research and Development Co.
Type: | Journal: Cellular and molecular neurobiology | Year: 2016

The NMDA receptor is the most widely studied ionotropic glutamate receptor, and it is central to many physiological and pathophysiological processes in the central nervous system. GluN2A is one of the two main types of GluN2 NMDA receptor subunits in the forebrain. The proper activity of GluN2A is important to brain function, as the abnormal regulation of GluN2A may induce some neuropsychiatric disorders. This review will examine the regulation of GluN2A by endogenous and exogenous regulators in the central nervous system.


PubMed | Hebei University of Science and Technology, Hebei Medical University and North China Pharmaceutical Group New Drug Research and Development Co.
Type: | Journal: Molecular neurobiology | Year: 2016

The NMDA receptor, which is heavily involved in several human brain diseases, is a heteromeric ligand-gated ion channel that interacts with multiple intracellular proteins through the C-termini of different subunits. GluN2A and GluN2B are the two primary types of GluN2 subunits in the forebrain. During the developmental period, there is a switch from GluN2B- to GluN2A-containing NMDA receptors in synapses. In the adult brain, GluN2A exists at synaptic sites more abundantly than GluN2B. GluN2A plays important roles not only in synaptic plasticity but also in mediating physiological functions, such as learning and memory. GluN2A has also been involved in many common human diseases, such as cerebral ischemia, seizure disorder, Alzheimers disease, and systemic lupus erythematosus. The following review investigates the functional and molecular properties, physiological functions, and pathophysiological roles of the GluN2A subunit.


Han L.,Northeastern University China | Huo P.,Shenyang University | Huo P.,North China Pharmaceutical Group Corporation New Drug Research and Development Co. | Chen H.,Yunnan University | And 8 more authors.
Chemistry and Biodiversity | Year: 2014

Six new nonactic and homononactic acid derivatives, ethyl homononactate (1), ethyl nonactate (2), homononactyl homononactate (6), ethyl homononactyl nonactate (7), ethyl homononactyl homononactate (8), and ethyl nonactyl nonactate (9), as well as four known compounds, homononactic acid (3), nonactic acid (4), homononactyl nonactate (5), and bishomononactic acid (10), were isolated from culture broth of Bacillus pumilus derived from Breynia fruticosa. The structures of new compounds were elucidated by spectroscopic analysis and chemical methods. The optical purities of 1-6 were determined by HPLC/MS after treatment with L-phenylalanine methyl ester. The dimeric compounds 5-9 showed weak cytotoxic activities against five human cancer cell lines (IC50 19-100 μg/ml). Copyright © 2014 Verlag Helvetica Chimica Acta AG, Zürich.


Cheng X.,North China Pharmaceutical Group New Drug Research and Development Co. | Wang Y.,North China Pharmaceutical Group New Drug Research and Development Co. | Zhang H.,North China Pharmaceutical Group New Drug Research and Development Co. | Niu C.,North China Pharmaceutical Group New Drug Research and Development Co.
Chinese Journal of Chromatography (Se Pu) | Year: 2012

A method was established for the determination of deoxyspergualin using reversedphase ion-pair chromatography (RP-IPC). Several parameters, such as the chromatographic column, the types and concentration of ion-pair reagents, the concentration of the buffer and the pH value of the mobile phase were evaluated. The optimal separation conditions were as follows: C18 column (250 mm × 4. 6 mm, 5 μm); mobile phase, 5 mmol / L di-potassium hydrogen phosphate (containing 5 mmol / L 1-pentanesulfonic acid sodium, pH 3. 6 ±0. 3)-acetonitrile (90: 10, v / v); flow rate, 1. 0 mL / min; detection wavelength, 210 nm; column temperature, 30 oC; injection volume, 20 μL. Under the optimaized experimental conditions, good linear relationships was obtained and the limit of detection for deoxyspergualin was 0. 5 mg / L.


PubMed | North China Pharmaceutical Group New Drug Research and Development Co.
Type: Journal Article | Journal: Se pu = Chinese journal of chromatography | Year: 2013

A method was established for the determination of deoxyspergualin using reversed-phase ion-pair chromatography (RP-IPC). Several parameters, such as the chromatographic column, the types and concentration of ion-pair reagents, the concentration of the buffer and the pH value of the mobile phase were evaluated. The optimal separation conditions were as follows: C18 column (250 mm x 4.6 mm, 5 microm); mobile phase, 5 mmol/L di-potassium hydrogen phosphate (containing 5 mmol/L 1-pentanesulfonic acid sodium, pH 3.6 +/- 0.3)-acetonitrile (90: 10, v/v); flow rate, 1.0 mL/min; detection wavelength, 210 nm; column temperature, 30 degrees C; injection volume, 20 microL. Under the optimaized experimental conditions, good linear relationships was obtained and the limit of detection for deoxyspergualin was 0.5 mg/L.

Loading North China Pharmaceutical Group New Drug Research and Development Co. collaborators
Loading North China Pharmaceutical Group New Drug Research and Development Co. collaborators